Clinical Trial Update: International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC

View source ↗

Summary

An international multicenter retrospective study will evaluate first-line therapy with enfortumab vedotin plus pembrolizumab (EV+P) in locally advanced or metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Padcev (enfortumab vedotin)

Snippet

Sponsor: Aron Research Foundation Ets | Conditions: Locally Advanced or Metastatic Urothelial Cancer, Urothelial Cancer | Status: NOT_YET_RECRUITING